lidocaine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 1579 137-58-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lignocaine
  • lidocaine
  • xylocain
  • dalcaine
  • duncaine
  • esracaine
  • solarcaine
  • lidocaine hydrochloride
  • lidocaine hydrochloride anhydrous
  • lidocaine hydrochloride hydrate
  • lidocaine HCl
A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
  • Molecular weight: 234.34
  • Formula: C14H22N2O
  • CLOGP: 1.95
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 32.34
  • ALOGS: -2.60
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.58 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 18.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 35 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.33 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 1948 FDA FRESENIUS KABI USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product adhesion issue 998.35 9.37 359 78764 4596 46602343
Product quality issue 419.13 9.37 401 78722 35247 46571692
Sinusitis 259.33 9.37 635 78488 129133 46477806
Anaesthetic complication 210.15 9.37 88 79035 1729 46605210
Local anaesthetic systemic toxicity 208.51 9.37 59 79064 319 46606620
Drug ineffective for unapproved indication 169.31 9.37 172 78951 16241 46590698
Anaphylactic shock 164.33 9.37 187 78936 20087 46586852
Toxic anterior segment syndrome 158.98 9.37 76 79047 2061 46604878
Methaemoglobinaemia 152.10 9.37 74 79049 2088 46604851
Completed suicide 150.16 9.37 32 79091 145888 46461051
Lagophthalmos 144.61 9.37 42 79081 253 46606686
Rheumatoid arthritis 133.84 9.37 126 78997 240089 46366850
Anaphylactic reaction 133.73 9.37 285 78838 52827 46554112
Infusion site erythema 119.45 9.37 101 79022 7541 46599398
Infusion site swelling 118.35 9.37 89 79034 5610 46601329
Cardiac arrest 106.22 9.37 366 78757 90033 46516906
Drug intolerance 97.08 9.37 65 79058 146984 46459955
Contraindicated product administered 89.81 9.37 14 79109 79933 46527006
Drug hypersensitivity 84.84 9.37 704 78419 243121 46363818
Incorrect route of product administration 80.55 9.37 118 79005 16265 46590674
Infusion site pruritus 76.50 9.37 54 79069 3084 46603855
Maternal exposure during delivery 76.26 9.37 34 79089 782 46606157
Infusion site pain 74.82 9.37 89 79034 10018 46596921
Stress cardiomyopathy 73.83 9.37 78 79045 7706 46599233
Pulseless electrical activity 73.71 9.37 75 79048 7092 46599847
Administration site swelling 70.50 9.37 36 79087 1129 46605810
Infusion site nodule 66.87 9.37 33 79090 961 46605978
Generalised tonic-clonic seizure 63.06 9.37 141 78982 26981 46579958
Bradycardia 59.24 9.37 246 78877 66052 46540887
Pemphigus 58.11 9.37 5 79118 45269 46561670
Infusion site extravasation 57.72 9.37 57 79066 5199 46601740
Administration site erythema 56.64 9.37 25 79098 561 46606378
Administration site pain 56.29 9.37 26 79097 651 46606288
Ventricular tachycardia 55.94 9.37 102 79021 16865 46590074
Type I hypersensitivity 54.03 9.37 39 79084 2307 46604632
General physical health deterioration 51.13 9.37 73 79050 115696 46491243
Abortion spontaneous 50.50 9.37 7 79116 43639 46563300
Seizure 49.70 9.37 368 78755 122686 46484253
Pulse absent 49.40 9.37 51 79072 4905 46602034
Joint swelling 47.41 9.37 135 78988 165938 46441001
Hand deformity 46.70 9.37 3 79120 34571 46572368
Unresponsive to stimuli 46.58 9.37 140 78983 32034 46574905
Sensory loss 46.57 9.37 58 79065 6844 46600095
Corneal oedema 46.45 9.37 31 79092 1615 46605324
Pneumocephalus 46.22 9.37 15 79108 137 46606802
Anaesthetic complication neurological 46.01 9.37 16 79107 184 46606755
Systemic lupus erythematosus 44.08 9.37 28 79095 65152 46541787
Suicide attempt 42.51 9.37 20 79103 55016 46551923
Procedural hypotension 42.25 9.37 26 79097 1176 46605763
Hepatic enzyme increased 41.93 9.37 46 79077 81741 46525198
Retinal vasculitis 41.35 9.37 21 79102 651 46606288
Ophthalmoplegia 41.27 9.37 23 79100 863 46606076
Upper respiratory tract infection 40.70 9.37 214 78909 63342 46543597
Synovitis 40.26 9.37 27 79096 61048 46545891
Apnoea 37.73 9.37 54 79069 7285 46599654
Treatment failure 36.99 9.37 63 79060 93024 46513915
Acute motor-sensory axonal neuropathy 36.29 9.37 16 79107 358 46606581
Psoriasis 35.25 9.37 49 79074 78555 46528384
Alopecia 34.91 9.37 149 78974 162265 46444674
Hypotension 34.61 9.37 570 78553 232019 46374920
Infusion site bruising 34.31 9.37 25 79098 1501 46605438
Ear infection 34.13 9.37 101 79022 22912 46584027
Application site rash 34.07 9.37 31 79092 2551 46604388
Bronchitis 33.09 9.37 299 78824 105680 46501259
Peripheral nerve injury 32.98 9.37 15 79108 362 46606577
Arthralgia 32.97 9.37 428 78695 364175 46242764
Platelet aggregation inhibition 32.75 9.37 11 79112 113 46606826
Body tinea 32.29 9.37 20 79103 915 46606024
Meningitis chemical 32.07 9.37 11 79112 121 46606818
Septic arthritis staphylococcal 31.54 9.37 15 79108 402 46606537
Acute kidney injury 31.14 9.37 253 78870 235602 46371337
Eyelid ptosis 31.04 9.37 45 79078 6143 46600796
Product preparation error 30.61 9.37 36 79087 4003 46602936
Infusion site haemorrhage 30.46 9.37 27 79096 2147 46604792
Ventricular fibrillation 30.43 9.37 63 79060 11433 46595506
Intentional self-injury 30.12 9.37 3 79120 24163 46582776
Mental status changes 29.93 9.37 136 78987 37952 46568987
Anterior chamber cell 29.75 9.37 16 79107 559 46606380
Anaphylactoid shock 29.44 9.37 13 79110 292 46606647
Glossodynia 28.73 9.37 20 79103 44353 46562586
Paralysis 28.20 9.37 52 79071 8669 46598270
Parophthalmia 28.14 9.37 12 79111 247 46606692
Bursitis infective 28.10 9.37 20 79103 1157 46605782
Systemic toxicity 28.01 9.37 7 79116 21 46606918
Corneal epithelium defect 27.76 9.37 13 79110 336 46606603
Fear of eating 27.73 9.37 13 79110 337 46606602
Myopathy toxic 27.24 9.37 12 79111 268 46606671
Post procedural complication 27.21 9.37 73 79050 15656 46591283
Lactic acidosis 26.69 9.37 12 79111 33897 46573042
Application site erythema 26.57 9.37 37 79086 4867 46602072
Condition aggravated 26.25 9.37 277 78846 244775 46362164
Spinal epidural haemorrhage 26.08 9.37 9 79114 101 46606838
Intentional overdose 25.75 9.37 44 79079 64900 46542039
Kounis syndrome 25.46 9.37 19 79104 1183 46605756
Bronchospasm 25.29 9.37 71 79052 15636 46591303
Spinal epidural haematoma 25.07 9.37 16 79107 772 46606167
Retinal artery occlusion 24.98 9.37 20 79103 1382 46605557
Renal injury 24.92 9.37 52 79071 9489 46597450
Incorrect drug administration rate 24.50 9.37 23 79100 1970 46604969
Spinal anaesthesia 24.41 9.37 7 79116 40 46606899
Embolia cutis medicamentosa 24.28 9.37 11 79112 263 46606676
Application site vesicles 24.22 9.37 20 79103 1444 46605495
Neurotoxicity 24.07 9.37 64 79059 13653 46593286
Conjunctival oedema 24.06 9.37 14 79109 571 46606368
Diplopia 24.02 9.37 80 79043 19325 46587614
Fear 24.00 9.37 71 79052 16101 46590838
Liver function test abnormal 23.98 9.37 26 79097 46461 46560478
C-reactive protein increased 23.87 9.37 39 79084 58551 46548388
Arthritis bacterial 23.53 9.37 38 79085 5698 46601241
Infusion site urticaria 23.39 9.37 15 79108 730 46606209
Arthropathy 23.31 9.37 70 79053 84630 46522309
C-reactive protein abnormal 23.26 9.37 4 79119 21266 46585673
Administration site extravasation 23.10 9.37 14 79109 616 46606323
Product contamination microbial 22.88 9.37 10 79113 219 46606720
Administration site pruritus 22.75 9.37 11 79112 306 46606633
Injury 22.74 9.37 140 78983 43887 46563052
Cyanosis 22.65 9.37 69 79054 15902 46591037
Upper airway obstruction 22.41 9.37 13 79110 527 46606412
Application site irritation 22.38 9.37 21 79102 1798 46605141
Anhedonia 22.11 9.37 52 79071 10283 46596656
Visual acuity reduced 22.10 9.37 85 79038 22028 46584911
Erythema 21.57 9.37 351 78772 142469 46464470
Unevaluable event 21.49 9.37 143 78980 46032 46560907
Anaphylactoid reaction 21.44 9.37 28 79095 3463 46603476
Administration site bruise 21.13 9.37 10 79113 265 46606674
Sopor 21.10 9.37 4 79119 19824 46587115
Drug reaction with eosinophilia and systemic symptoms 20.94 9.37 12 79111 29536 46577403
Procedural complication 20.69 9.37 33 79090 4897 46602042
Extradural haematoma 20.59 9.37 18 79105 1405 46605534
Airway peak pressure increased 20.43 9.37 10 79113 286 46606653
Emotional distress 20.06 9.37 104 79019 30603 46576336
Cauda equina syndrome 19.95 9.37 13 79110 650 46606289
Administration site irritation 19.76 9.37 6 79117 43 46606896
Infusion site rash 19.74 9.37 15 79108 960 46605979
Atonic urinary bladder 19.64 9.37 7 79116 87 46606852
Administration site reaction 19.61 9.37 9 79114 222 46606717
Pericarditis 19.57 9.37 8 79115 23919 46583020
Mydriasis 19.29 9.37 50 79073 10503 46596436
Staphylococcal infection 19.27 9.37 115 79008 35656 46571283
Infection susceptibility increased 19.20 9.37 21 79102 2158 46604781
Administration site nodule 19.19 9.37 6 79117 48 46606891
Leukopenia 19.15 9.37 56 79067 68287 46538652
Arachnoiditis 19.12 9.37 10 79113 330 46606609
Trigeminal palsy 19.10 9.37 5 79118 19 46606920
Infusion site reaction 19.08 9.37 19 79104 1750 46605189
Glossoptosis 18.98 9.37 6 79117 50 46606889
Anaesthesia oral 18.76 9.37 4 79119 4 46606935
Post-traumatic neuralgia 18.76 9.37 4 79119 4 46606935
Headache 18.71 9.37 990 78133 477362 46129577
Application site discomfort 18.71 9.37 10 79113 345 46606594
Punctate keratitis 18.58 9.37 12 79111 591 46606348
Infusion site warmth 18.55 9.37 16 79107 1227 46605712
Anaesthesia 18.47 9.37 6 79117 55 46606884
Infusion site mass 18.32 9.37 14 79109 904 46606035
Arthritis 17.81 9.37 69 79054 77247 46529692
Cranial nerve palsies multiple 17.67 9.37 5 79118 27 46606912
Epidural haemorrhage 17.59 9.37 7 79116 120 46606819
Sinus tachycardia 17.53 9.37 78 79045 21571 46585368
Propionibacterium infection 17.37 9.37 5 79118 29 46606910
Abdominal discomfort 17.35 9.37 168 78955 150997 46455942
Respiratory tract infection 17.21 9.37 98 79025 29874 46577065
Neuromuscular block prolonged 17.16 9.37 11 79112 535 46606404
Hyponatraemia 17.15 9.37 101 79022 101231 46505708
Tryptase increased 17.15 9.37 8 79115 205 46606734
Tachycardia 17.01 9.37 250 78873 99372 46507567
Wound 16.96 9.37 29 79094 42773 46564166
Nerve block 16.79 9.37 10 79113 426 46606513
Endophthalmitis 16.68 9.37 24 79099 3254 46603685
Hip arthroplasty 16.63 9.37 5 79118 18107 46588832
Respiratory depression 16.34 9.37 50 79073 11550 46595389
Aspiration joint abnormal 16.15 9.37 3 79120 0 46606939
Removal of foreign body 16.00 9.37 4 79119 12 46606927
Nystagmus 15.99 9.37 32 79091 5667 46601272
Device expulsion 15.83 9.37 14 79109 27528 46579411
Environmental exposure 15.81 9.37 6 79117 90 46606849
Uterine hypertonus 15.78 9.37 7 79116 159 46606780
Injection site hypoaesthesia 15.76 9.37 9 79114 354 46606585
Cutis laxa 15.74 9.37 7 79116 160 46606779
Diarrhoea 15.71 9.37 782 78341 558820 46048119
Blood pressure decreased 15.70 9.37 157 78966 57002 46549937
Body dysmorphic disorder 15.66 9.37 7 79116 162 46606777
Third stage postpartum haemorrhage 15.54 9.37 4 79119 14 46606925
Hypoxia 15.53 9.37 145 78978 51693 46555246
Inhibitory drug interaction 15.48 9.37 18 79105 1977 46604962
Impaired quality of life 15.43 9.37 23 79100 3219 46603720
Laryngeal oedema 15.09 9.37 30 79093 5289 46601650
Psoriatic arthropathy 15.02 9.37 24 79099 36355 46570584
Application site burn 14.91 9.37 12 79111 836 46606103
Epidural analgesia 14.83 9.37 5 79118 52 46606887
Pain 14.81 9.37 967 78156 475981 46130958
Foetal heart rate abnormal 14.61 9.37 10 79113 543 46606396
Diplegia 14.57 9.37 13 79110 1043 46605896
Injection site ulcer 14.42 9.37 10 79113 555 46606384
Incision site rash 14.40 9.37 4 79119 20 46606919
Injection site oedema 14.38 9.37 11 79112 711 46606228
Application site pain 14.30 9.37 25 79098 3998 46602941
Therapeutic product effect incomplete 14.26 9.37 76 79047 78077 46528862
Extradural abscess 14.23 9.37 11 79112 722 46606217
Cardiac failure congestive 14.21 9.37 94 79029 91656 46515283
Lower respiratory tract infection 14.12 9.37 47 79076 55042 46551897
Blood creatinine increased 14.10 9.37 74 79049 76329 46530610
Flail chest 14.07 9.37 3 79120 3 46606936
Chemical burn of gastrointestinal tract 14.07 9.37 3 79120 3 46606936
Spinal cord oedema 14.05 9.37 6 79117 124 46606815
Ventricular extrasystoles 14.04 9.37 46 79077 11017 46595922
Mobility decreased 14.00 9.37 54 79069 60540 46546399
Chorea 13.72 9.37 13 79110 1127 46605812
Pupils unequal 13.70 9.37 14 79109 1330 46605609
Orbital infection 13.65 9.37 4 79119 25 46606914
Knee arthroplasty 13.63 9.37 12 79111 23653 46583286
Psychotic disorder 13.61 9.37 11 79112 22610 46584329
Blood methaemoglobin present 13.55 9.37 5 79118 69 46606870
Inadequate analgesia 13.39 9.37 20 79103 2804 46604135
Dermatitis contact 13.35 9.37 37 79086 8086 46598853
Febrile neutropenia 13.34 9.37 230 78893 94397 46512542
Anal sphincter atony 13.33 9.37 7 79116 233 46606706
Haemorrhagic vasculitis 13.30 9.37 5 79118 73 46606866
Loss of personal independence in daily activities 13.19 9.37 51 79072 57132 46549807
Toxicity to various agents 13.13 9.37 460 78663 211306 46395633
No adverse event 13.02 9.37 101 79022 34130 46572809
Hypoaesthesia eye 12.94 9.37 5 79118 79 46606860
Shock 12.92 9.37 72 79051 21773 46585166
Eye infarction 12.79 9.37 4 79119 32 46606907
Myelitis transverse 12.69 9.37 12 79111 1037 46605902
Delayed recovery from anaesthesia 12.68 9.37 11 79112 850 46606089
Vitritis 12.57 9.37 11 79112 860 46606079
Nerve injury 12.57 9.37 35 79088 7670 46599269
Corneal abrasion 12.49 9.37 11 79112 867 46606072
Accidental overdose 12.45 9.37 67 79056 19999 46586940
Drug resistance 12.38 9.37 7 79116 17361 46589578
Quadriplegia 12.37 9.37 15 79108 1722 46605217
Harlequin syndrome 12.28 9.37 4 79119 37 46606902
Arteriospasm coronary 12.23 9.37 22 79101 3599 46603340
Monoplegia 12.08 9.37 18 79105 2518 46604421
Hereditary angioedema 12.07 9.37 28 79095 5488 46601451
Type IV hypersensitivity reaction 12.06 9.37 18 79105 2522 46604417
Urticaria 12.05 9.37 273 78850 117619 46489320
Application site alopecia 12.00 9.37 3 79120 9 46606930
Eosinophilia 12.00 9.37 9 79114 19208 46587731
Apnoeic attack 12.00 9.37 7 79116 287 46606652
Cholestasis of pregnancy 11.99 9.37 12 79111 1112 46605827
Spinal cord infarction 11.95 9.37 7 79116 289 46606650
Hepatotoxicity 11.81 9.37 15 79108 24994 46581945
Status epilepticus 11.80 9.37 51 79072 13928 46593011
Blood cholesterol increased 11.79 9.37 32 79091 39981 46566958
Hypoaesthesia oral 11.73 9.37 42 79081 10517 46596422
Fear-related avoidance of activities 11.68 9.37 5 79118 104 46606835
Pallor 11.54 9.37 73 79050 23093 46583846
Coronary artery disease 11.52 9.37 25 79098 33727 46573212
Vascular resistance systemic decreased 11.50 9.37 5 79118 108 46606831
Hemiplegic migraine 11.50 9.37 4 79119 46 46606893
Paraplegia 11.41 9.37 17 79106 2377 46604562
Infusion site induration 11.32 9.37 10 79113 792 46606147
Septic shock 11.29 9.37 55 79068 57838 46549101
Injection site abscess 11.28 9.37 11 79112 988 46605951
Rhabdomyolysis 11.27 9.37 35 79088 41874 46565065
Helicobacter infection 11.22 9.37 3 79120 11733 46595206
Administration site scar 11.20 9.37 4 79119 50 46606889
Loss of consciousness 11.17 9.37 251 78872 107987 46498952
Foetal exposure during pregnancy 11.15 9.37 22 79101 30725 46576214
Airway complication of anaesthesia 11.12 9.37 6 79117 211 46606728
Blood pressure immeasurable 11.11 9.37 12 79111 1215 46605724
Tumour pain 11.10 9.37 12 79111 1217 46605722
Treatment noncompliance 11.01 9.37 21 79102 29710 46577229
Genital ulceration 10.98 9.37 8 79115 480 46606459
Injection site ischaemia 10.97 9.37 3 79120 14 46606925
Facial asymmetry 10.93 9.37 9 79114 647 46606292
Retinal haemorrhage 10.92 9.37 25 79098 4858 46602081
Cytokine release syndrome 10.88 9.37 29 79094 6194 46600745
Blood pressure fluctuation 10.85 9.37 22 79101 30426 46576513
Pneumonia mycoplasmal 10.84 9.37 10 79113 838 46606101
Hepatocellular injury 10.81 9.37 21 79102 29501 46577438
Blepharoplasty 10.80 9.37 3 79120 15 46606924
Arthritis fungal 10.80 9.37 3 79120 15 46606924
Left ventricle outflow tract obstruction 10.75 9.37 6 79117 226 46606713
Cataract nuclear 10.74 9.37 10 79113 848 46606091
Syringomyelia 10.73 9.37 4 79119 57 46606882
Spinal cord compression 10.72 9.37 21 79102 3663 46603276
Application site pruritus 10.63 9.37 22 79101 3991 46602948
Cough 10.62 9.37 303 78820 229946 46376993
Swelling face 10.62 9.37 137 78986 52922 46554017
Skin discolouration 10.60 9.37 93 79030 32587 46574352
No reaction on previous exposure to drug 10.58 9.37 5 79118 132 46606807
Red blood cell sedimentation rate increased 10.53 9.37 14 79109 22875 46584064
Myocardial infarction 10.52 9.37 110 79013 97418 46509521
Stridor 10.47 9.37 19 79104 3128 46603811
Weight decreased 10.36 9.37 275 78848 210574 46396365
Oesophageal adenocarcinoma recurrent 10.34 9.37 3 79120 18 46606921
Pupillary reflex impaired 10.31 9.37 15 79108 2053 46604886
Electrocardiogram QRS complex shortened 10.31 9.37 7 79116 375 46606564
Brow ptosis 10.31 9.37 6 79117 245 46606694
Product contamination 10.20 9.37 8 79115 537 46606402
Neurogenic shock 10.20 9.37 6 79117 250 46606689
Brain cancer metastatic 10.19 9.37 4 79119 66 46606873
Meningitis 10.13 9.37 28 79095 6108 46600831
Allodynia 10.07 9.37 8 79115 547 46606392
Infusion site discolouration 10.05 9.37 8 79115 548 46606391
Procedural haemorrhage 10.05 9.37 16 79107 2370 46604569
Injection site vesicles 10.05 9.37 17 79106 2648 46604291
Exophthalmos 10.03 9.37 11 79112 1134 46605805
Retinal scar 10.03 9.37 5 79118 149 46606790
Glucose tolerance impaired 10 9.37 24 79099 4807 46602132
Musculoskeletal stiffness 9.97 9.37 112 79011 97881 46509058
Skin test positive 9.91 9.37 9 79114 739 46606200
Asthenia 9.84 9.37 429 78694 310646 46296293
Cerebral congestion 9.82 9.37 3 79120 22 46606917
Myxoedema coma 9.79 9.37 7 79116 408 46606531
Vocal cord paralysis 9.79 9.37 13 79110 1635 46605304
Peripheral swelling 9.77 9.37 199 78924 157872 46449067
Lip swelling 9.70 9.37 75 79048 25320 46581619
Ophthalmological examination abnormal 9.63 9.37 4 79119 77 46606862
Urinary tract infection 9.63 9.37 461 78662 219805 46387134
Administration site rash 9.58 9.37 4 79119 78 46606861
Retinal cyst 9.58 9.37 4 79119 78 46606861
Procedural pain 9.57 9.37 46 79077 13133 46593806
Anorgasmia 9.54 9.37 8 79115 590 46606349
Interstitial lung disease 9.54 9.37 53 79070 53896 46553043
Product use in unapproved indication 9.52 9.37 210 78913 90063 46516876
Electrocardiogram ST segment elevation 9.49 9.37 20 79103 3675 46603264
Post procedural drainage 9.49 9.37 3 79120 25 46606914
Back pain 9.48 9.37 441 78682 209598 46397341
Ophthalmic herpes simplex 9.45 9.37 6 79117 287 46606652

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product adhesion issue 396.60 10.42 128 44112 1337 29906901
Anaphylactic shock 224.07 10.42 177 44063 13816 29894422
Anaphylactic reaction 209.98 10.42 232 44008 27750 29880488
Anaesthetic complication 204.67 10.42 72 44168 997 29907241
Methaemoglobinaemia 154.30 10.42 75 44165 2435 29905803
Product quality issue 131.12 10.42 150 44090 18624 29889614
Ventricular tachycardia 108.50 10.42 154 44086 23708 29884530
Toxic anterior segment syndrome 104.31 10.42 49 44191 1472 29906766
Cardiac arrest 96.45 10.42 329 43911 92521 29815717
Drug ineffective 90.08 10.42 830 43410 339557 29568681
Lagophthalmos 84.54 10.42 21 44219 73 29908165
Sinusitis 80.28 10.42 162 44078 33183 29875055
Fear 76.43 10.42 87 44153 10738 29897500
Hypotension 76.35 10.42 532 43708 200033 29708205
Local anaesthetic systemic toxicity 71.85 10.42 21 44219 152 29908086
Injury 70.43 10.42 120 44120 21611 29886627
Renal injury 69.17 10.42 86 44154 11643 29896595
Completed suicide 64.81 10.42 33 44207 99459 29808779
Generalised tonic-clonic seizure 63.41 10.42 108 44132 19443 29888795
Ventricular fibrillation 63.41 10.42 94 44146 15044 29893194
Anhedonia 56.95 10.42 66 44174 8303 29899935
Emotional distress 55.02 10.42 90 44150 15675 29892563
Anaesthetic complication neurological 50.81 10.42 19 44221 316 29907922
Unevaluable event 50.46 10.42 131 44109 31654 29876584
Pain 49.51 10.42 429 43811 172212 29736026
Bradycardia 48.83 10.42 209 44031 65317 29842921
Unresponsive to stimuli 43.08 10.42 110 44130 26309 29881929
Electrocardiogram ST segment elevation 42.55 10.42 42 44198 4400 29903838
Mydriasis 39.40 10.42 47 44193 6096 29902142
Drug ineffective for unapproved indication 39.17 10.42 63 44177 10817 29897421
Infusion site pain 39.16 10.42 32 44208 2618 29905620
Bronchospasm 38.78 10.42 61 44179 10277 29897961
Retinal artery occlusion 37.51 10.42 26 44214 1658 29906580
Endophthalmitis 37.29 10.42 35 44205 3445 29904793
Embolia cutis medicamentosa 36.24 10.42 13 44227 191 29908047
Ear infection 35.60 10.42 49 44191 7325 29900913
General physical health deterioration 34.60 10.42 59 44181 99885 29808353
Tachycardia 34.31 10.42 206 44034 73533 29834705
Infusion site swelling 33.79 10.42 24 44216 1592 29906646
Ventricular extrasystoles 32.82 10.42 60 44180 11414 29896824
Sinus tachycardia 32.27 10.42 71 44169 15433 29892805
Delayed recovery from anaesthesia 31.39 10.42 17 44223 694 29907544
Spinal cord infarction 31.22 10.42 12 44228 216 29908022
Oculocardiac reflex 31.18 10.42 9 44231 62 29908176
Amaurosis 29.37 10.42 16 44224 661 29907577
Psoriasis 29.34 10.42 13 44227 42493 29865745
Stress 28.68 10.42 80 44160 20155 29888083
Interstitial lung disease 28.60 10.42 28 44212 60169 29848069
Infusion site pruritus 28.27 10.42 15 44225 587 29907651
Apnoea 27.85 10.42 40 44200 6218 29902020
Wrong product administered 27.45 10.42 34 44206 4584 29903654
Toxicity to various agents 27.08 10.42 389 43851 176794 29731444
Removal of foreign body 26.88 10.42 6 44234 11 29908227
Anal sphincter atony 26.78 10.42 8 44232 63 29908175
Infusion site erythema 26.71 10.42 21 44219 1625 29906613
Ophthalmoplegia 26.42 10.42 19 44221 1285 29906953
Respiratory arrest 26.32 10.42 99 44141 29159 29879079
Administration site pain 26.07 10.42 10 44230 179 29908059
Intracranial hypotension 25.73 10.42 11 44229 263 29907975
Myocardial infarction 25.72 10.42 97 44143 125528 29782710
Respiratory depression 25.45 10.42 54 44186 11449 29896789
Drug interaction 24.67 10.42 183 44057 199385 29708853
Electrocardiogram QRS complex prolonged 24.64 10.42 31 44209 4246 29903992
Cyanosis 24.10 10.42 54 44186 11881 29896357
Blindness 24.08 10.42 55 44185 12254 29895984
Accidental overdose 23.72 10.42 70 44170 18205 29890033
Post procedural complication 23.61 10.42 53 44187 11673 29896565
Procedural complication 23.41 10.42 31 44209 4466 29903772
Hypoxia 22.44 10.42 134 44106 47720 29860518
Foreign body 22.42 10.42 16 44224 1069 29907169
Cardiotoxicity 22.32 10.42 30 44210 4384 29903854
Reperfusion arrhythmia 21.86 10.42 7 44233 71 29908167
Anxiety 21.50 10.42 215 44025 89656 29818582
Infusion site nodule 21.44 10.42 7 44233 76 29908162
Infusion site extravasation 20.87 10.42 22 44218 2491 29905747
Electrocardiogram T wave amplitude increased 20.58 10.42 6 44234 43 29908195
Infusion site bruising 20.54 10.42 9 44231 229 29908009
Incorrect route of product administration 20.43 10.42 49 44191 11266 29896972
Upper respiratory tract infection 19.95 10.42 87 44153 27389 29880849
Tracheitis 19.85 10.42 12 44228 605 29907633
Injection site ulcer 19.77 10.42 9 44231 251 29907987
Circulatory collapse 19.52 10.42 70 44170 20144 29888094
Retinal vasculitis 19.17 10.42 9 44231 270 29907968
Rheumatoid arthritis 18.61 10.42 20 44220 41177 29867061
Tonic convulsion 18.60 10.42 13 44227 840 29907398
Induration 18.56 10.42 13 44227 843 29907395
Loss of consciousness 18.55 10.42 189 44051 79186 29829052
Erythema 18.38 10.42 185 44055 77266 29830972
Blood methaemoglobin present 18.36 10.42 5 44235 27 29908211
Haemodynamic instability 18.16 10.42 38 44202 7977 29900261
Paraplegia 18.13 10.42 21 44219 2640 29905598
Product contamination physical 17.91 10.42 5 44235 30 29908208
Tryptase increased 17.75 10.42 8 44232 218 29908020
Sinus arrest 17.67 10.42 16 44224 1504 29906734
Type I hypersensitivity 17.37 10.42 13 44227 935 29907303
Allergic respiratory disease 17.13 10.42 5 44235 36 29908202
Shock 17.07 10.42 73 44167 22786 29885452
Hyperthermia malignant 16.94 10.42 17 44223 1817 29906421
Administration site irritation 16.81 10.42 4 44236 11 29908227
Jaundice 16.75 10.42 14 44226 32472 29875766
Melaena 16.70 10.42 14 44226 32423 29875815
Hypoxic-ischaemic encephalopathy 16.68 10.42 27 44213 4660 29903578
International normalised ratio increased 16.67 10.42 28 44212 47711 29860527
Carboxyhaemoglobinaemia 16.56 10.42 3 44237 0 29908238
Application site alopecia 16.56 10.42 3 44237 0 29908238
Seizure 16.55 10.42 220 44020 98255 29809983
Acute kidney injury 16.50 10.42 295 43945 273547 29634691
Vitreous floaters 16.33 10.42 22 44218 3222 29905016
Pallor 16.32 10.42 68 44172 20981 29887257
Cauda equina syndrome 16.15 10.42 9 44231 389 29907849
Pulse absent 16.14 10.42 29 44211 5444 29902794
Administration site swelling 16.09 10.42 7 44233 175 29908063
Anaphylactoid shock 15.73 10.42 9 44231 409 29907829
Oxygen saturation decreased 15.72 10.42 114 44126 43326 29864912
Neurotoxicity 15.70 10.42 49 44191 13133 29895105
Corneal oedema 15.62 10.42 14 44226 1298 29906940
Brain oedema 15.62 10.42 47 44193 12351 29895887
Myopathy toxic 15.61 10.42 9 44231 415 29907823
Chondrolysis 15.56 10.42 6 44234 109 29908129
Cardiac failure congestive 15.49 10.42 68 44172 84339 29823899
Hepatic enzyme increased 15.42 10.42 16 44224 33478 29874760
Application site erythema 15.40 10.42 18 44222 2285 29905953
Chemical burn 15.39 10.42 7 44233 195 29908043
Trigemino-cardiac reflex 15.31 10.42 6 44234 114 29908124
Coronary artery disease 14.87 10.42 32 44208 49680 29858558
Otospondylomegaepiphyseal dysplasia 14.76 10.42 6 44234 126 29908112
Hyperaesthesia 14.69 10.42 22 44218 3551 29904687
Administration site reaction 14.64 10.42 5 44235 63 29908175
Pancreatitis acute 14.62 10.42 10 44230 25685 29882553
Airway complication of anaesthesia 14.58 10.42 6 44234 130 29908108
Drug hypersensitivity 14.53 10.42 160 44080 68359 29839879
Conjunctival scar 14.50 10.42 5 44235 65 29908173
Laryngeal oedema 14.48 10.42 21 44219 3293 29904945
Suicide attempt 14.28 10.42 20 44220 36677 29871561
Product contamination microbial 14.23 10.42 10 44230 652 29907586
Diabetes mellitus 14.21 10.42 25 44215 41840 29866398
Application site oedema 14.19 10.42 4 44236 25 29908213
Vitritis 14.03 10.42 10 44230 667 29907571
Anterior chamber cell 13.86 10.42 8 44232 370 29907868
Myokymia 13.84 10.42 5 44235 75 29908163
Mental status changes 13.81 10.42 98 44142 36981 29871257
Diarrhoea 13.81 10.42 382 43858 333721 29574517
Injection site joint infection 13.80 10.42 4 44236 28 29908210
Neuromuscular blockade 13.79 10.42 6 44234 150 29908088
Overdose 13.58 10.42 187 44053 84150 29824088
Opisthotonus 13.47 10.42 8 44232 390 29907848
Adrenergic syndrome 13.27 10.42 5 44235 85 29908153
Agranulocytosis 13.22 10.42 8 44232 21934 29886304
Urticaria 13.22 10.42 131 44109 54475 29853763
Weight decreased 13.16 10.42 151 44089 150770 29757468
Arthritis infective 13.11 10.42 18 44222 2684 29905554
Diabetic retinal oedema 13.08 10.42 7 44233 279 29907959
Inadequate analgesia 13.08 10.42 18 44222 2690 29905548
Oral lichen planus 13.06 10.42 6 44234 171 29908067
Rhabdomyolysis 13.06 10.42 49 44191 63531 29844707
Eye inflammation 13.01 10.42 14 44226 1623 29906615
Oesophageal obstruction 13.01 10.42 8 44232 416 29907822
Periorbital oedema 12.99 10.42 20 44220 3306 29904932
Testicular torsion 12.96 10.42 3 44237 7 29908231
Sleep deficit 12.95 10.42 8 44232 419 29907819
Blood pressure decreased 12.93 10.42 116 44124 46959 29861279
Administration related reaction 12.86 10.42 5 44235 93 29908145
Kounis syndrome 12.75 10.42 14 44226 1659 29906579
Cerebral venous thrombosis 12.66 10.42 9 44231 598 29907640
Blood pressure fluctuation 12.64 10.42 5 44235 17498 29890740
Angina pectoris 12.60 10.42 15 44225 29503 29878735
Drug-induced liver injury 12.48 10.42 8 44232 21266 29886972
Pulmonary fibrosis 12.40 10.42 4 44236 15886 29892352
Procedural hypotension 12.33 10.42 11 44229 1014 29907224
Hepatitis 12.33 10.42 9 44231 22347 29885891
Myalgia 12.18 10.42 65 44175 76602 29831636
Suspected transmission of an infectious agent via product 12.16 10.42 8 44232 468 29907770
Status epilepticus 12.14 10.42 40 44200 11032 29897206
Extradural abscess 12.13 10.42 9 44231 639 29907599
Drug intolerance 12.07 10.42 31 44209 45260 29862978
Diplopia 11.88 10.42 46 44194 13726 29894512
Symblepharon 11.88 10.42 5 44235 115 29908123
Ventricular arrhythmia 11.73 10.42 22 44218 4266 29903972
Leukopenia 11.71 10.42 43 44197 56116 29852122
Condition aggravated 11.60 10.42 139 44101 137727 29770511
Penile vascular disorder 11.56 10.42 3 44237 13 29908225
Retrognathia 11.33 10.42 6 44234 234 29908004
Application site irritation 11.32 10.42 9 44231 708 29907530
Procedural pain 11.32 10.42 24 44216 5085 29903153
Drug resistance 11.24 10.42 8 44232 20125 29888113
Arthritis bacterial 11.11 10.42 22 44218 4442 29903796
Burning sensation 11.08 10.42 51 44189 16423 29891815
Posterior capsule rupture 11.04 10.42 3 44237 16 29908222
Cardiac procedure complication 10.90 10.42 6 44234 253 29907985
Skin graft 10.86 10.42 8 44232 562 29907676
Fear of eating 10.78 10.42 4 44236 65 29908173
Palatal oedema 10.76 10.42 9 44231 761 29907477
Ocular retrobulbar haemorrhage 10.75 10.42 3 44237 18 29908220
Infusion site irritation 10.74 10.42 5 44235 147 29908091
Injection site pain 10.65 10.42 79 44161 30231 29878007
Administration site pruritus 10.61 10.42 3 44237 19 29908219
Mean arterial pressure decreased 10.53 10.42 5 44235 154 29908084
Post herpetic neuralgia 10.48 10.42 10 44230 1005 29907233
Respiratory paralysis 10.46 10.42 4 44236 71 29908167
Nuchal rigidity 10.42 10.42 6 44234 276 29907962

Pharmacologic Action:

SourceCodeDescription
ATC C01BB01 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ib
ATC C05AD01 CARDIOVASCULAR SYSTEM
VASOPROTECTIVES
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
Local anesthetics
ATC D04AB01 DERMATOLOGICALS
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
Anesthetics for topical use
ATC N01BB02 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC R02AD02 RESPIRATORY SYSTEM
THROAT PREPARATIONS
THROAT PREPARATIONS
Anesthetics, local
ATC S01HA07 SENSORY ORGANS
OPHTHALMOLOGICALS
LOCAL ANESTHETICS
Local anesthetics
ATC S02DA01 SENSORY ORGANS
OTOLOGICALS
OTHER OTOLOGICALS
Analgesics and anesthetics
ATC N01BB52 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0000897 Amides
FDA EPC N0000175426 Antiarrhythmic
FDA EPC N0000175682 Amide Local Anesthetic
MeSH PA D000777 Anesthetics
MeSH PA D000779 Anesthetics, Local
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:36333 local anesthetics
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:88188 allergenic drug
FDA PE N0000175976 Local Anesthesia

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Postherpetic neuralgia indication 2177002
Neuralgia indication 16269008
Urethritis indication 31822004 DOID:1343
Premature ejaculation indication 44001008 DOID:13709
Ventricular arrhythmia indication 44103008
Hemorrhoids indication 70153002 DOID:9746
Infestation by Phthirus pubis indication 71011005 DOID:13760
Pediculosis capitis indication 81000006 DOID:5501
Pruritus ani indication 90446007
Infestation by Sarcoptes scabiei var hominis indication 128869009 DOID:8295
Local anesthetic intrathecal block indication 231249005
Skin irritation indication 367466007
Local anesthesia indication 386761002
Itching of skin indication 418363000
Suppression of the Gag Reflex indication
Local Anesthesia for Ophthalmologic Procedure indication
Mouth Irritation indication
Minor Skin Wound Pain indication
Regional Anesthesia for Ophthalmologic Surgery indication
Local Anesthesia for Endotracheal Intubation indication
Local Anesthesia for Urethral Pain indication
Prevent Minor Bacterial Skin Infection indication
Neuropathic pain off-label use 247398009
Inflammatory dermatosis off-label use 703938007
Mycosis contraindication 3218000 DOID:1564
Gastritis contraindication 4556007 DOID:4029
Alcoholism contraindication 7200002
Psoriasis contraindication 9014002 DOID:8893
Bacterial septicemia contraindication 10001005 DOID:0040085
Sinus tachycardia contraindication 11092001
Measles contraindication 14189004 DOID:8622
Lowered convulsive threshold contraindication 19260006
Cirrhosis of liver contraindication 19943007 DOID:5082
Myocardial infarction contraindication 22298006 DOID:5844
Atopic dermatitis contraindication 24079001 DOID:3310
Abscess of intestine contraindication 24557004
Acute tuberculosis contraindication 25629007
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypovolemia contraindication 28560003
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Gastrointestinal fistula contraindication 37831005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Body fluid retention contraindication 43498006
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Stokes-Adams syndrome contraindication 46935006
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Atrial fibrillation contraindication 49436004 DOID:0060224
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Sinus bradycardia contraindication 49710005
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Corneal opacity contraindication 64634000
Blood coagulation disorder contraindication 64779008 DOID:1247
Osteoporosis contraindication 64859006 DOID:11476
Cerebral arteriosclerosis contraindication 65312002
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Factor II deficiency contraindication 73975000
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Gastrointestinal hemorrhage contraindication 74474003
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Open-angle glaucoma contraindication 84494001 DOID:1067
Herpes simplex contraindication 88594005 DOID:8566
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Hemophilia contraindication 90935002
Corneal ulcer contraindication 91514001 DOID:8463
Disorder of skin contraindication 95320005 DOID:37
Disorder of mucous membrane contraindication 95351003
Anemia due to enzyme deficiency contraindication 111577008
Magnetic resonance imaging contraindication 113091000
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Ophthalmic herpes simplex contraindication 186542001
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Partial atrioventricular block contraindication 195039008
Heart block contraindication 233916004
Anastomosis of intestine contraindication 235407009
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Sepsis syndrome contraindication 238150007
Telangiectasia disorder contraindication 247479008
Diverticulitis of gastrointestinal tract contraindication 271366000
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Varicella-zoster virus infection contraindication 309465005
Deficiency of cholinesterase contraindication 360607009
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Pseudomembranous enterocolitis contraindication 397683000
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Denuded skin contraindication 418242004
Uncontrolled Epilepsy contraindication
Intracerebral Mass contraindication
Lidocaine Toxicity contraindication
Reduced Hepatic Blood Flow contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.4 acidic
pKa2 7.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1.8% ZTLIDO SCILEX PHARMS INC N207962 Feb. 28, 2018 RX PATCH TOPICAL Feb. 28, 2021 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel protein type 2 subunit alpha Ion channel BLOCKER UNKNOWN CHEMBL
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER Kd 4.80 IUPHAR CHEMBL
Sodium channel protein type 10 subunit alpha Ion channel BLOCKER UNKNOWN CHEMBL
Sodium channel protein type 4 subunit alpha Ion channel BLOCKER IC50 5.70 CHEMBL CHEMBL
Sodium channel protein type 9 subunit alpha Ion channel BLOCKER IC50 4.54 CHEMBL CHEMBL
Sodium channel protein type 3 subunit alpha Ion channel BLOCKER IC50 4.98 CHEMBL CHEMBL
Acetylcholine receptor Ion channel IC50 4.95 WOMBAT-PK
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 3.56 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel IC50 3.30 WOMBAT-PK
Sodium channel protein type X alpha subunit Unclassified BLOCKER IC50 4 IUPHAR
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.25 CHEMBL
Sodium channel protein type 5 subunit alpha Unclassified BLOCKER IC50 4.20 IUPHAR

External reference:

IDSource
4018262 VUID
N0000146592 NUI
D00358 KEGG_DRUG
6108-05-0 SECONDARY_CAS_RN
4017992 VANDF
4018262 VANDF
C0242375 UMLSCUI
CHEBI:50512 CHEBI
LQZ PDB_CHEM_ID
CHEMBL79 ChEMBL_ID
CHEMBL541521 ChEMBL_ID
CHEMBL1200409 ChEMBL_ID
D008012 MESH_DESCRIPTOR_UI
DB00281 DRUGBANK_ID
3676 PUBCHEM_CID
2623 IUPHAR_LIGAND_ID
4202 INN_ID
98PI200987 UNII
1299236 RXNORM
14031 MMSL
4977 MMSL
4978 MMSL
73102 MMSL
9242 MMSL
d00059 MMSL
000626 NDDF
000627 NDDF
001350 NDDF
001351 NDDF
387480006 SNOMEDCT_US
61773008 SNOMEDCT_US
82573000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lidocaine Viscous HUMAN PRESCRIPTION DRUG LABEL 1 0054-0548 SOLUTION 20 mg ORAL ANDA 20 sections
Lidocaine Viscous HUMAN PRESCRIPTION DRUG LABEL 1 0054-3500 SOLUTION 20 mg ORAL ANDA 20 sections
Lidocaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3505 SOLUTION 40 mg TOPICAL ANDA 18 sections
Lidocaine HUMAN OTC DRUG LABEL 1 0113-0135 AEROSOL, SPRAY 0.64 g TOPICAL OTC monograph not final 14 sections
basic care endure HUMAN OTC DRUG LABEL 1 0113-7200 SPRAY 10 mg TOPICAL OTC monograph final 16 sections
basic care lidocaine HUMAN OTC DRUG LABEL 1 0113-7219 PATCH 560 mg TOPICAL OTC monograph not final 14 sections
basic care lidocaine HUMAN OTC DRUG LABEL 1 0113-7700 PATCH 560 mg TOPICAL OTC monograph not final 14 sections
Good Sense endure HUMAN OTC DRUG LABEL 1 0113-8000 SPRAY 10 mg TOPICAL OTC monograph final 16 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0115-1468 CREAM 25 mg TOPICAL ANDA 20 sections
Lidocaine Viscous HUMAN PRESCRIPTION DRUG LABEL 1 0121-0903 SOLUTION 20 mg ORAL ANDA 20 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9575 INJECTION, SOLUTION 20 mg INFILTRATION ANDA 12 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9576 INJECTION, SOLUTION 20 mg INFILTRATION ANDA 12 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9577 INJECTION, SOLUTION 10 mg INFILTRATION ANDA 12 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9578 INJECTION, SOLUTION 10 mg INFILTRATION ANDA 12 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9579 INJECTION, SOLUTION 10 mg INFILTRATION ANDA 12 sections
Lidocaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9594 INJECTION, SOLUTION 20 mg EPIDURAL ANDA 12 sections
Lidocaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9595 INJECTION, SOLUTION 10 mg EPIDURAL ANDA 12 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0168-0204 OINTMENT 50 mg TOPICAL ANDA 21 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0168-0357 CREAM 25 mg TOPICAL ANDA 25 sections
LIDOCAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0264-9376 INJECTION 10 mg INFILTRATION ANDA 12 sections
Lidocaine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 2 0264-9594 INJECTION, SOLUTION 0.40 g INTRAVENOUS NDA 23 sections
Lidocaine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 2 0264-9598 INJECTION, SOLUTION 0.80 g INTRAVENOUS NDA 23 sections
SunBurnt PLUS Pain Relief HUMAN OTC DRUG LABEL 1 0295-1110 GEL 1 g TOPICAL OTC MONOGRAPH NOT FINULLL 15 sections
Lidocaine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-0409 INJECTION, SOLUTION 4 mg INTRAVENOUS NDA 24 sections
Lidocaine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-0411 INJECTION, SOLUTION 8 mg INTRAVENOUS NDA 24 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 1 0362-0221 OINTMENT 5 g TOPICAL ANDA 22 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0262 INJECTION, SOLUTION 20 mg SUBCUTANEOUS ANDA 23 sections
Lidocaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0898 INJECTION, SOLUTION 20 mg SUBCUTANEOUS ANDA 23 sections
Lignospan Standard HUMAN PRESCRIPTION DRUG LABEL 2 0362-1095 INJECTION, SOLUTION 20 mg SUBCUTANEOUS ANDA 23 sections
Lignospan Forte HUMAN PRESCRIPTION DRUG LABEL 2 0362-1096 INJECTION, SOLUTION 20 mg SUBCUTANEOUS ANDA 23 sections